The Second Xiangya Hospital of Central South University, China reports positive patient outcomes, including resolution of all somatic anxiety symptoms and improved sleep quality
The efficacy persisted after four months of follow-up
HOUSTON, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) — Nexalin Technologies, Inc. (the “Company” or “Nexalin”) (NASDAQ: NXL; NXLIW) Announced today the release of a white paper titled “A case of Nexalin ADI in the treatment of somatic symptoms of anxiety,” at the Second Xiangya Hospital of Central South University in China, validating the company’s tACS device for the treatment of generalized anxiety disorder. The white paper details a case study of the university’s use of Nexalin’s tACS device for the treatment of generalized anxiety disorder, in which the hospital reported all Disappearance of somatic anxiety symptoms and improvement in sleep quality.This case study was overseen by the National Center for Clinical Research on Mental Disorders.
The Second Xiangya Hospital of Central South University issued the following statement: “We are delighted to partner with Nexalin to bring this new, effective, safe, drug-free therapy to our patients with psychiatric and neurodegenerative diseases. We Encouraged by the results of this patient with generalized anxiety disorder who was treated with a 15 mA Nexalin tACS device. Treatment consisted of 2 treatments a day for more than 10 days. The patient was a 42-year-old female teacher who had been unwell for 23 years, Anxiety, sleep disturbance for 6 months. Her condition was diagnosed with systemic somatic symptoms caused by severe anxiety. We observed elimination of all somatic symptoms and significant improvement in sleep quality caused by excessive anxiety. This case report demonstrates the Nexalin tACS device Value and effectiveness in the treatment of insomnia, anxiety and somatic symptoms in this patient. Also, the effect was immediate without any side effects. Importantly, the treatment effect persisted after a 4-month follow-up. The results of this trial were greatly expanded The possibility of more effective treatments for people with generalized anxiety disorder while eliminating concerns associated with side effects of psychiatric medications. We therefore look forward to conducting larger clinical studies.”
The Second Xiangya Hospital was founded in 1958 and is affiliated to Central South University, the largest first-class hospital in Hunan Province. According to the ranking of Chinese hospitals by Fudan University, the hospital ranks 13th in overall strength and 15th in specialties. The hospital has 3,500 beds, 40 clinical departments, 9 medical laboratories, 127 wards, and 4,985 employees.
Nexalin’s tACS technology is a safe, drug-free, non-invasive treatment initially used to treat patients with anxiety, depression and insomnia. Nexalin has now developed a patented tACS device that generates a 15 mA waveform designed to penetrate structures deep in the midbrain associated with various mental health disorders. It is believed that Nexalin’s 15 mA waveform will correct irregularities in the brain’s neurochemical system. Low levels of serotonin (serotonin, 5-HT) in the brain’s neurochemical system have been linked to a variety of mental health problems. In 2021, Nexalin’s tACS device was approved by China’s National Medical Products Administration (NMPA) for insomnia and depression.
Mark White, CEO of Nexalin Technology, stated: “We are proud to have our neurostimulation technology featured in a white paper from this prestigious university hospital. This white paper reinforces the growing body of clinical evidence supporting Nexalin’s 15 mA device. , we believe this can have a significant impact on improving mental health care outcomes for patients with generalized anxiety disorder. As healthcare providers learn that our neurostimulation technology provides a proven alternative to psychiatric medications, our medical The adoption of the device is expected to enhance mental health care. Nexalin is designed to improve the treatment of generalized anxiety disorder and other neurodegenerative disorders. Nexalin’s team is leading the industry in clinical research on neurostimulation for the treatment of mental disorders. We intend to bring our Our expertise is applied to therapeutic applications such as Substance Use Disorder (SUD), Alzheimer’s and chronic pain. Our mission is to aggressively expand market awareness of our breakthrough technology globally.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable by the human body, providing relief to people with mental health issues without adverse side effects. Nexalin utilizes bioelectronic medical technology to treat mental health problems without the need for medication or psychotherapy. Nexalin believes the 15-milliamp medical device could penetrate structures deep in the midbrain associated with mental health disorders. Nexalin believes the deeper penetrating waveform will produce enhanced patient responses without any adverse side effects. The Nexalin tACS device was recently approved by the National Medical Products Administration (NMPA) in China for the treatment of insomnia and depression. In September 2018, Nexalin entered into a series of agreements with Wider Come Limited (“Wider”), a company incorporated under the laws of the People’s Republic of China. Under the agreement, Nexalin and Wider have agreed to explore the formation of a Hong Kong-domiciled joint venture entity. This new entity will conduct clinical studies and implement business distribution plans for the Nexalin device in the Asia Pacific region. For more information about the company, please visit: https://nexalin.com/.
This press release contains statements that constitute “forward-looking statements,” including statements regarding the company’s initial public offering. Forward-looking statements are subject to a number of conditions, many of which are beyond the company’s control, including the risk factors section of the company’s registration statement and those set forth in the offering prospectus filed with the Securities and Exchange Commission. A copy is available on the SEC’s website at www.sec.gov. The company undertakes no obligation to update these statements for revisions or changes after the date of this press release, unless required by law.
Crescendo Communications LLC
Phone: (212) 671-1020